The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

[1]  D. Catovsky,et al.  Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation , 2010, Haematologica.

[2]  M. Dyer,et al.  Drug cross‐resistance and therapy‐induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing , 2009, British journal of haematology.

[3]  R. Rosenquist,et al.  In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia – rolipram and prednisolone active in cells from patients with poor prognosis , 2009, European journal of haematology.

[4]  J. García-Marco,et al.  Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.

[5]  P. Loehrer.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2008 .

[6]  R. Braziel,et al.  Drug resistance in B‐cell chronic lymphocytic leukemia: Predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay , 2007, Cytometry. Part B, Clinical cytometry.

[7]  D. Catovsky,et al.  High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities , 2003, Annals of Hematology.

[8]  R. Rosenquist,et al.  Ex vivo drug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells. , 2003, Leukemia research.

[9]  E. Montserrat,et al.  In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[10]  S. Richards,et al.  Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay , 1999, British journal of haematology.

[11]  Sandra K. Johnson,et al.  In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues – correlation with clinical course , 1998, Leukemia.

[12]  V. Callea,et al.  In vitro drug‐induced cytotoxicity predicts clinical response to fludarabine in B‐cell chronic lymphocytic leukaemia , 1998, British journal of haematology.

[13]  A. Harris,et al.  Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. , 1997, British Journal of Cancer.

[14]  E. Newcomb,et al.  Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. , 1994, Blood.